How the diabetes gene TCF7L2 controls different metabolic zones in the liver
The Regulation of Hepatic Metabolic Zonation by the Diabetes Gene TCF7L2
Researchers are looking at how the diabetes-linked gene TCF7L2 changes the way different parts of the liver work, with the goal of helping people with type 2 diabetes and fatty liver disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11249136 on NIH RePORTER |
What this research studies
From my perspective, the team is using a special mouse model that turns off TCF7L2 in the liver and combining cell studies, genome mapping, and whole-animal physiology to see how liver regions are organized. They will map chromatin accessibility (ATAC‑seq) and other genomic signals to find which metabolic pathways are controlled in each liver zone. The researchers want to know whether disruption of this zonation contributes to scarring and disease in nonalcoholic steatohepatitis (NASH). Findings could point to pathways to target in future human treatments for diabetes-related liver disease.
Who could benefit from this research
Good fit: Adults with type 2 diabetes, especially those with fatty liver disease or NASH, are the patient group most likely to follow or benefit from future clinical applications of this work.
Not a fit: People without metabolic liver disease or without type 2 diabetes (for example, most people with type 1 diabetes or unrelated conditions) are unlikely to benefit directly from these findings in the near term.
Why it matters
Potential benefit: If successful, this work could reveal new targets to prevent or reduce liver scarring and metabolic problems in people with type 2 diabetes and NASH.
How similar studies have performed: Prior laboratory studies showed TCF7L2 influences many metabolic genes in liver cells, but translating those findings into treatments for NASH or diabetes remains largely untested.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Norton, Luke — University of Texas Hlth Science Center
- Study coordinator: Norton, Luke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.